Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2010

View Archived Issues

Schering Plough receives approval for Temodal in Japan

Natural product IDN-5706 has beneficial effects in mouse model of AD

Curemark initiates enrollment into phase III clinical trials of CM-AT in the U.S.

EMEA initiates review of Amsterdam MolecularTherapeutics' MAA for Glybera in LPLD

Dynavax Technologies reports phase Ib data on SD-101 in chronic hepatitis C

INSYS Therapeutics completes efficacy trial of fentanyl sublingual spray

Shionogi launches peramivir in Japan

Envoy Therapeutics and Merck & Co. enter into diabetes and obesity collaboration

Romiplostim appears to be safe in MDS patients with thrombocytopenia

Penwest enters into fourth research and development agreement with Otsuka

Novel modulator of mitochondrial membrane potential shows antidiabetic effects in mice

Preclinical activity of novel mitotic kinesin inhibitor supports clinical evaluation in cancer

FDA approves Novo Nordisk's Victoza for certain adults with type 2 diabetes

Ambrilia discloses HIV integrase inhibitors for the prevention and treatment of AIDS

U.S. Army claims BoNT/A LC inhibitors for the treatment of C. botulinum infection

Telik initiates phase I trial of ezatiostat in patients with myelodysplastic syndrome

Bayer Schering describes novel adenosine A1 agonists for the treatment of CAD

Concert presents alpha2-adrenoceptor agonists for motor function disorders

PI3K and mTOR inhibitors in early development at Wyeth

Roche identifies novel tachykinin NK3 receptor antagonists as antipsychotics

New protein kinase inhibitors for the treatment of cancer discovered at Plexxikon

Prometheus Laboratories acquires exclusive rights to Proleukin in the U.S.

Amgen reports results from fourth quarter of 2009

China Aoxing completes phase III registration study of tilidine for moderate to severe pain

FDA reschedules review of NDA for Theratechnologies' tesamorelin

Dainippon obtains Japanese approval for additional indication for Meropen

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...